Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors [PDF]
Molecules, 2016 Chiral HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) are of great interest since one enantiomer is often more potent than the corresponding counterpart against the HIV-1 wild type (WT) and the HIV-1 drug resistant mutant strains.
Valeria Famiglini, Romano Silvestri
doaj +4 more sources
Effect of reverse transcriptase inhibitors on LINE-1 and Ty1 reverse transcriptase activities and on LINE-1 retrotransposition [PDF]
, 2011 Background LINE-1s (L1, Long Interspersed Element-1) are the most abundant autonomous non-LTR retrotransposons in the human genome and replicate by reverse transcription of an RNA intermediate.
Lixin Dai, Qing Huang, Jef D Boeke
core +1 more source
Protein expression from unintegrated HIV-1 DNA introduces bias in primary in vitro post-integration latency models [PDF]
, 2016 To understand the persistence of latently HIV-1 infected cells in virally suppressed infected patients, a number of in vitro models of HIV latency have been developed.
Bonczkowski, Pawel +7 more
core +1 more source
Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières [PDF]
, 2008 OBJECTIVES: To describe the use of second-line protease-inhibitor regimens in Médecins Sans Frontières HIV programmes, and determine switch rates, clinical outcomes, and factors associated with survival.
Alexandra Calmy +24 more
core +2 more sources
Lipometabolic side-effects of three ritonavir-boosted double protease inhibitor regimens without reverse transcriptase inhibitors [PDF]
, 2008 Poster presentation: Purpose of the study To compare the lipometabolic profiles of three double-boosted protease inhibitor (PI) regimens at standard dose, containing saquinavir and ritonavir in combination with lopinavir (LOPSAQ), atazanavir (ATSAQ) or ...
Bickel, Markus +8 more
core +1 more source
Anti-HIV-1 activity of benzothiadiazine dioxide [PDF]
, 2013 Antiviral assays carried out on the potent benzothiadiazine dioxide (BTD) human cytomegalovirus (HCMV) inhibitors have led us to find marginal but selective anti-HIV-1 activity.
Balzarini, Jan +7 more
core +2 more sources
HIV - recentes avanços na pesquisa de fármacos HIV - highlights in drug research
Química Nova, 2008 The development of new antiretroviral drugs is a dynamic process that is continuously fueled by identification of new molecular targets and new compounds for know targets.
Wilson Cunico +2 more
doaj +1 more source
A Review of Electroanalytical Techniques for Determination of Anti-HIV Drugs
International Journal of Electrochemistry, 2011 Until now after the human immunodeficiency virus (HIV) was discovered as the then tentative aetiological agent of acquired immune deficiency syndrome (AIDS), exactly 25 anti-HIV compounds have been formally approved for clinical use in the treatment of ...
Burçin Bozal +2 more
doaj +1 more source
The Molecular Docking of Specific Reverse Transcriptase Inhibitory Ligands onto the Molecular Model of HIV-1 Reverse Transcriptase [PDF]
Trends in Pharmaceutical SciencesHIV-1 reverse transcriptase (RT) is a crucial enzyme in HIV replication and AIDS progression. It consists of p66 and p51 subunits and converts viral RNA into double-stranded DNA for integration into the host cell's genome.
Roohallah Yousefi
doaj +1 more source
Nature Communications, 2021 Initiation of HIV-1 reverse transcription occurs at the host tRNALys 3, which forms a complex with the 5’ end of the HIV-1 viral RNA and reverse transcriptase (RT).
Betty Ha +7 more
doaj +1 more source